000180416 001__ 180416
000180416 005__ 20240229145618.0
000180416 0247_ $$2doi$$a10.1093/ije/dyac124
000180416 0247_ $$2pmid$$apmid:35726641
000180416 0247_ $$2ISSN$$a0300-5771
000180416 0247_ $$2ISSN$$a1464-3685
000180416 0247_ $$2altmetric$$aaltmetric:130002031
000180416 037__ $$aDKFZ-2022-01319
000180416 041__ $$aEnglish
000180416 082__ $$a610
000180416 1001_ $$00000-0001-9229-2589$$aWatts, Eleanor L$$b0
000180416 245__ $$aCirculating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis.
000180416 260__ $$aOxford$$bOxford Univ. Press$$c2023
000180416 3367_ $$2DRIVER$$aarticle
000180416 3367_ $$2DataCite$$aOutput Types/Journal article
000180416 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1676294200_32051
000180416 3367_ $$2BibTeX$$aARTICLE
000180416 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180416 3367_ $$00$$2EndNote$$aJournal Article
000180416 500__ $$a2023 Feb 8;52(1):71-86
000180416 520__ $$aPrevious studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer.Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium.In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I.These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease.
000180416 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000180416 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180416 650_7 $$2Other$$aInsulin-like growth factor-I
000180416 650_7 $$2Other$$aMendelian randomization
000180416 650_7 $$2Other$$aaggressive prostate cancer
000180416 650_7 $$2Other$$ainternational consortia
000180416 650_7 $$2Other$$aprospective analysis
000180416 650_7 $$2Other$$aprostate cancer
000180416 7001_ $$00000-0002-5652-356X$$aPerez-Cornago, Aurora$$b1
000180416 7001_ $$aFensom, Georgina K$$b2
000180416 7001_ $$aSmith-Byrne, Karl$$b3
000180416 7001_ $$aNoor, Urwah$$b4
000180416 7001_ $$aAndrews, Colm D$$b5
000180416 7001_ $$aGunter, Marc J$$b6
000180416 7001_ $$00000-0001-6617-0879$$aHolmes, Michael V$$b7
000180416 7001_ $$aMartin, Richard M$$b8
000180416 7001_ $$aTsilidis, Konstantinos K$$b9
000180416 7001_ $$aAlbanes, Demetrius$$b10
000180416 7001_ $$aBarricarte, Aurelio$$b11
000180416 7001_ $$aBueno-de-Mesquita, H Bas$$b12
000180416 7001_ $$aCohn, Barbara A$$b13
000180416 7001_ $$00000-0002-3359-420X$$aDeschasaux-Tanguy, Melanie$$b14
000180416 7001_ $$aDimou, Niki L$$b15
000180416 7001_ $$aFerrucci, Luigi$$b16
000180416 7001_ $$00000-0002-3650-0475$$aFlicker, Leon$$b17
000180416 7001_ $$aFreedman, Neal D$$b18
000180416 7001_ $$00000-0003-4946-9099$$aGiles, Graham G$$b19
000180416 7001_ $$00000-0002-6123-0219$$aGiovannucci, Edward L$$b20
000180416 7001_ $$aHaiman, Christopher A$$b21
000180416 7001_ $$aHankey, Graham J$$b22
000180416 7001_ $$aHolly, Jeffrey M P$$b23
000180416 7001_ $$00000-0002-7808-9477$$aHuang, Jiaqi$$b24
000180416 7001_ $$aHuang, Wen-Yi$$b25
000180416 7001_ $$aHurwitz, Lauren M$$b26
000180416 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b27$$udkfz
000180416 7001_ $$aKubo, Tatsuhiko$$b28
000180416 7001_ $$aLe Marchand, Loic$$b29
000180416 7001_ $$aMacInnis, Robert J$$b30
000180416 7001_ $$aMännistö, Satu$$b31
000180416 7001_ $$aMetter, E Jeffrey$$b32
000180416 7001_ $$aMikami, Kazuya$$b33
000180416 7001_ $$aMucci, Lorelei A$$b34
000180416 7001_ $$00000-0003-4788-503X$$aOlsen, Anja W$$b35
000180416 7001_ $$00000-0002-5637-1383$$aOzasa, Kotaro$$b36
000180416 7001_ $$aPalli, Domenico$$b37
000180416 7001_ $$aPenney, Kathryn L$$b38
000180416 7001_ $$00000-0003-3676-8954$$aPlatz, Elizabeth A$$b39
000180416 7001_ $$aPollak, Michael N$$b40
000180416 7001_ $$aRoobol, Monique J$$b41
000180416 7001_ $$aSchaefer, Catherine A$$b42
000180416 7001_ $$aSchenk, Jeannette M$$b43
000180416 7001_ $$00000-0002-8306-0687$$aStattin, Pär$$b44
000180416 7001_ $$aTamakoshi, Akiko$$b45
000180416 7001_ $$aThysell, Elin$$b46
000180416 7001_ $$aTsai, Chiaojung Jillian$$b47
000180416 7001_ $$00000-0002-8322-8857$$aTouvier, Mathilde$$b48
000180416 7001_ $$aVan Den Eeden, Stephen K$$b49
000180416 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b50
000180416 7001_ $$aWeinstein, Stephanie J$$b51
000180416 7001_ $$aWilkens, Lynne R$$b52
000180416 7001_ $$aYeap, Bu B$$b53
000180416 7001_ $$aPRACTICAL Consortium, CRUK, BPC, CAPS, PEGASUS$$b54$$eCollaboration Author
000180416 7001_ $$aAllen, Naomi E$$b55
000180416 7001_ $$aKey, Timothy J$$b56
000180416 7001_ $$aTravis, Ruth C$$b57
000180416 7001_ $$aEeles, Rosalind A$$b58
000180416 7001_ $$aHaiman, Christopher A$$b59
000180416 7001_ $$aKote-Jarai, Zsofia$$b60
000180416 7001_ $$aSchumacher, Fredrick R$$b61
000180416 7001_ $$aBenlloch, Sara$$b62
000180416 7001_ $$aOlama, Ali Amin Al$$b63
000180416 7001_ $$aMuir, Kenneth R$$b64
000180416 7001_ $$aBerndt, Sonja I$$b65
000180416 7001_ $$aConti, David V$$b66
000180416 7001_ $$aWiklund, Fredrik$$b67
000180416 7001_ $$aChanock, Stephen$$b68
000180416 7001_ $$aWang, Ying$$b69
000180416 7001_ $$aTangen, Catherine M$$b70
000180416 7001_ $$aBatra, Jyotsna$$b71
000180416 7001_ $$aClements, Judith A$$b72
000180416 773__ $$0PERI:(DE-600)1494592-7$$a10.1093/ije/dyac124$$gp. dyac124$$n1$$p71-86$$tInternational journal of epidemiology$$v52$$x0300-5771$$y2023
000180416 909CO $$ooai:inrepo02.dkfz.de:180416$$pVDB
000180416 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000180416 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000180416 9141_ $$y2022
000180416 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000180416 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000180416 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000180416 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000180416 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J EPIDEMIOL : 2022$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000180416 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J EPIDEMIOL : 2022$$d2023-10-21
000180416 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000180416 980__ $$ajournal
000180416 980__ $$aVDB
000180416 980__ $$aI:(DE-He78)C020-20160331
000180416 980__ $$aUNRESTRICTED